BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+9.82%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.17B
AUM Growth
+$18.1M
(+0.29%)
Cap. Flow
-$269M
Cap. Flow
% of AUM
-4.35%
Top 10 Holdings %
Top 10 Hldgs %
39.22%
Holding
177
New
11
Increased
57
Reduced
71
Closed
15
Top Buys
| 1 |
Evolent Health
EVH
|
$28.3M |
| 2 |
Exact Sciences
EXAS
|
$19.8M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$19.6M |
| 4 |
Abbott
ABT
|
$15.7M |
| 5 |
Inspire Medical Systems
INSP
|
$14.8M |
Top Sells
| 1 |
Bio-Rad Laboratories Class A
BIO
|
$36.5M |
| 2 |
Insmed
INSM
|
$36.2M |
| 3 |
argenx
ARGX
|
$32M |
| 4 |
Charles River Laboratories
CRL
|
$31.4M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$30.5M |
Sector Composition
| 1 | Healthcare | 99.93% |
| 2 | Industrials | 0.04% |
| 3 | Communication Services | 0.02% |
| 4 | Technology | 0.01% |
| 5 | Consumer Discretionary | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Castle Biosciences
CSTL
$673M
| $36M | 0.58% |
1,262,030
+44,929
| +4% | +$1.28M |
|
|
VRNA
52
Verona Pharma
VRNA
$9.18B
| $35.1M | 0.57% |
1,220,059
+85,830
| +8% | +$2.47M |
|
53
Veeva Systems
VEEV
$44.4B
| $34.3M | 0.56% |
163,512
-5,071
| -3% | -$1.06M |
|
54
Globus Medical
GMED
$7.94B
| $33.6M | 0.54% |
469,798
-27,495
| -6% | -$1.97M |
|
55
Wave Life Sciences
WVE
$1.27B
| $33.6M | 0.54% |
4,094,458
| – | – |
|
56
Thermo Fisher Scientific
TMO
$183B
| $33.2M | 0.54% |
53,623
+10,997
| +26% | +$6.8M |
|
57
Axsome Therapeutics
AXSM
$6.09B
| $33M | 0.53% |
367,181
-149,352
| -29% | -$13.4M |
|
58
MacroGenics
MGNX
$121M
| $32.7M | 0.53% |
9,929,963
-12,350
| -0.1% | -$40.6K |
|
|
SAGE
59
DELISTED
Sage Therapeutics
SAGE
| $32.2M | 0.52% |
4,460,693
-4,000
| -0.1% | -$28.9K |
|
60
IQVIA
IQV
$31.4B
| $30.8M | 0.5% |
129,827
+37,744
| +41% | +$8.94M |
|
61
Annexon
ANNX
$225M
| $30.5M | 0.49% |
5,157,290
| – | – |
|
62
Danaher
DHR
$143B
| $29.4M | 0.48% |
105,590
+21,670
| +26% | +$6.02M |
|
63
CRISPR Therapeutics
CRSP
$4.82B
| $28.7M | 0.46% |
610,000
-7,649
| -1% | -$359K |
|
64
Regeneron Pharmaceuticals
REGN
$59.8B
| $28.1M | 0.46% |
26,776
-5,521
| -17% | -$5.8M |
|
65
Structure Therapeutics
GPCR
$1.14B
| $27.6M | 0.45% |
629,758
+72,437
| +13% | +$3.18M |
|
66
Transmedics
TMDX
$3.65B
| $26.7M | 0.43% |
169,844
-31,571
| -16% | -$4.96M |
|
67
NeoGenomics
NEO
$1.06B
| $23.8M | 0.39% |
1,612,612
+410,516
| +34% | +$6.06M |
|
68
Molina Healthcare
MOH
$9.6B
| $23.3M | 0.38% |
67,562
-8,831
| -12% | -$3.04M |
|
|
69
BioMarin Pharmaceuticals
BMRN
$11.3B
| $23.3M | 0.38% |
330,976
+278,744
| +534% | +$19.6M |
|
70
Steris
STE
$23.9B
| $22.1M | 0.36% |
91,282
| – | – |
|
71
Hologic
HOLX
$14.7B
| $20.2M | 0.33% |
247,864
+38
| +0% | +$3.1K |
|
72
SI-BONE Inc
SIBN
$700M
| $20.2M | 0.33% |
1,444,109
+56,500
| +4% | +$790K |
|
73
Privia Health
PRVA
$2.85B
| $19.3M | 0.31% |
1,059,171
| – | – |
|
74
McKesson
MCK
$85.9B
| $17.7M | 0.29% |
35,742
-10,400
| -23% | -$5.14M |
|
75
Natera
NTRA
$23B
| $17.6M | 0.28% |
138,459
-75,528
| -35% | -$9.59M |
|